Rick Newitter

Did you say you have an incremental 50 to 100 basis point headwind that you are now contemplating in 2Q to 4Q that is getting absorbed in your reiterated gross margin guidance

is that a reasonable place and way to think about it or anything else you would call out

can you describe what's in your base case for any kind of competitive dynamics, possibly even intensifying with Abbott coming out with a dual analyte

You talked about opportunity to take share as consolidation disruption is unfolding. Can you just update us on what you're seeing on that front?

how much of the underlying market strength or pickup in recent quarters or years is attributable to that? And I'm just trying to get a sense for how sustainable a high single-digit growth profile

how much of the momentum you're seeing there from last quarter or the last few quarters, is that indication versus converting to marketing initiatives direct to patients

Could you just quantify kind of what percentage of the market this potentially just gives you reaccess to

my understanding was that med surg is, you know, over the long-range plan, I would presume in 'twenty-six as well. About positive 100 to 200 basis points

What's your view on fully autonomous robotic your competitor obviously has a solution or wants a solution there

just curious if you can comment at all on U.S. neovascular end market, particularly in the schemics growth

Are you starting to see -- maybe not for the 2025 fiscal years and budget, but are there any behavior changes that are going on?

It seems like there's potential to generate real savings to the system here, better patient management post surgery

what is it that ROSA is going to do for the marketplace that Monogram isn't going to use SARPE

If you could just elaborate a little more on what exactly that is, what prompted it